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Abstract
Background: Estrogen and androgen have been linked to the regulation of circulating hepatocyte growth factor (HGF), an
adipose tissue-derived cytokine. It is possible that the CYP19A1 gene which alters sex hormones production may influence
HGF levels. We examined the association between the CYP19A1 gene variants and plasma HGF concentrations.
Design: We evaluated 45 common and putative functional variants of CYP19A1 and circulating levels of HGF among 260
postmenopausal women who later developed colorectal cancer from the Women’s Health Initiative Observational Cohort.
As the distribution of HGF levels was highly skewed, we transformed HGF concentrations for all women into a log-, ranked-,
or normal score-scale value. Multiple linear regression with adjustment for age was used to evaluate the associations.
Results: We observed an association between the rs7172156, rs1008805, rs6493494, rs749292, and rs11636639 variants and
HGF levels in ranked and normal score scales (corrected p values #0.02), although the association of these 5 SNPs with log-
scale HGF was not significant (corrected p values $0.16). The associations remained unchanged after additional adjustment
for hormone therapy use and estradiol levels. These 5 SNPs, which were in linkage disequilibrium (pairwise D9$97%,
r
2$56%), constituted a block with 2 common haplotypes accounting for 82% frequency. The most common haplotype,
TCCCA, was associated with lower ranked- or normal score-transformed HGF levels (corrected p values #0.001), whereas the
second most common haplotype, CTTCA, was associated with higher ranked- or normal score-transformed HGF levels
(corrected p values #0.02).
Conclusion: Our findings of a potential association between the CYP19A1 variants and circulating HGF levels warrant
confirmation in studies with larger sample size.
Citation: Lin JH, Gunter MJ, Manson JE, Rexrode KM, Cook NR, et al. (2012) The Aromatase Gene (CYP19A1) Variants and Circulating Hepatocyte Growth Factor in
Postmenopausal Women. PLoS ONE 7(7): e42079. doi:10.1371/journal.pone.0042079
Editor: Yury E. Khudyakov, Centers for Disease Control and Prevention, United States of America
Received February 15, 2012; Accepted July 2, 2012; Published July 25, 2012
Copyright:  2012 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by grants CA123089, CA126846, and HL088521 from the National Institutes of Health. The WHI program is funded by
contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221 from the National Heart, Lung,
and Blood Institute, National Institutes of Health, United States Department of Health and Human Services. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jhlin@rics.bwh.harvard.edu
. These authors contributed equally to this work.
Introduction
Obesity contributes to the development of a variety of common
chronic diseases among postmenopausal women, including
cardiometabolic diseases and several cancers. Accumulation of
adipose tissue as a result of excess body weight is associated with
an increase of secretion of adipocytokines and growth factors
including tumor necrosis factor alpha (TNF-a), interleukins (ILs),
and insulin-like growth factor 1 (IGF1) [1–3]. Circulating
hepatocyte growth factor (HGF), a less-studied adipokine to date,
has been found to be elevated .3-fold in obese individuals than in
those of normal body size [4]. Circulating HGF levels are also
positively associated with risk for obesity-related clinical outcomes
including hypertension [5], type 2 diabetes [6], and ischemic
stroke [7]. It has been shown that HGF acts as an angiogenic
growth factor in an autocrine and paracrine fashion in various cell
types to promote cell migration, proliferation, invasion, and blood
vessel growth [8].
Although it is clear that excess adiposity elevates HGF levels, the
mechanisms underlying the regulation of HGF levels remain
unknown. Experimental studies in animals and cell lines have
shown that HGF expression are elevated by sex steroids including
estradiol and testosterone [9–11] and the activation of HGF
pathway is regulated by estrogen and androgen signaling [12,13].
Aromatase is the key enzyme in estrogen biosynthesis which
converts androstenedione to estrone and testosterone to estradiol
[14]. Excess adiposity has been linked to increased aromatase
activity, and, thus, increased estrogen production among post-
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e42079menopausal women [15]. It is further possible that elevated
aromatase activity, resulting from excess adiposity, alters sex
steroids production which leads to changes in HGF levels.
Recent familial aggregation studies have reported significant
parent-offspring and sibling correlations with HGF levels, inde-
pendent of age and obesity-related phenotypes, suggesting that
HGF secretion is also under genetic control [16]. Previous studies
have shown that circulating HGF levels are associated with several
tagging SNPs of the HGF gene [17]. Additionally, HGF levels are
regulated by genes containing cis-acting elements including
activating protein-1 (AP1), specificity protein 1 (SP1), and
interferon regulatory factor-1 (IRF-1), and GATA [18]. CYP19A1,
which encodes the aromatase enzyme and resides on chromosome
15q21.1, is one such gene that contains several of these regulatory
elements (eg, AP1, SP1) in its promoter region [19,20]. Given also
that variation of the CYP19A1 gene is associated with circulating
estradiol and testosterone levels [21–23] which likely affect HGF
levels, it is possible that genetic variants of the CYP19A1 gene may
be linked to HGF levels.
To test the genetic association between the aromatase enzyme
and circulating HGF levels, we, therefore, conducted an evalua-
tion of common and putative functional variants in the CYP19A1
gene in relation to circulating HGF levels among postmenopausal
women.
Results
We first evaluated the distribution of transformed HGF levels by
plotting each of the transformed HGF levels against normal
quantiles (Figure 1). The distribution of HGF appeared to be
improved after each transformation. As can be seen from
Figure 1B, some extreme values were still seen at both ends in
the log-transformed HGF distribution. The outliers were some-
what improved in the ranked distribution (Figure 1C), and then
resolved in the normal score-transformed distribution (Figure 1D).
When we tested the 3 transformed distribution with the Shapiro-
Wilk test, only normal score-transformed distribution had a non-
significant p value of .0.05.
Two of the 47 SNPs were removed because of an MAF of ,5%
(Table S1). We also excluded 22 individuals who were missing
.20% of genotype data and 1 with missing HGF levels, resulting
in a total of 260 women in the present analysis. Circulating HGF
levels were modestly correlated with body mass index (BMI) and
cytokines of TNF-a and IL-6 (Spearman correlation coefficients
were between 0.2 and 0.3, p values #0.005). In addition,
circulating HGF was not associated with estradiol and total
IGF1 levels in either users or nonusers of hormone therapy (HT)
(Spearman correlation coefficients #0.10, p values $0.36),
although levels of estradiol and IGF1 were each significantly
different between HT users and nonusers [24]. Table 1 presents
the selected characteristics according to the tertile distribution for
HGF levels. Women in the highest group of circulating HGF were
more likely to be obese and have higher plasma levels of TNF-a
and IL-6, but were less likely to receive current hormone therapy.
Circulating levels of estradiol and total or free IGF1 appeared to
be similar across HGF groups in either users or non-users of HT.
The estradiol levels in the 3 HGF groups were 47.0, 40.1, and 49.8
(p value=0.49) among HT users, and 11.7, 12.8, and 13.3 (p
value=0.29) among nonusers. The total IGF levels in the HGF
tertiles were 109.7, 118.6, and 95.3 (p value=0.77) among HT
users, and 145.8, 138.3, and 145.8 (p value=0.80) among
nonusers.
Among the 45 variants evaluated, we found that six variants
residing in the intronic region were associated with log-, ranked-,
and normal score-transformed HGF levels with a pointwise p
value of ,0.05. When multiple comparisons were accounted for, 5
among them remained significantly associated with both ranked-
and normal-scale HGF values (p values #0.04) (Table 2).
Specifically, each additional copy of the minor allele of
rs7172156 (T) and rs1008805 (C) was associated with lower mean
HGF levels (Table 2). In contrast, the minor alleles of rs6493494
(T), rs749292 (T), and rs11636639 (C) were each associated with
higher HGF levels (Table 2). The associations remained
unchanged when we additionally adjusted for estradiol levels
and current use of HT (data not shown). The associations were
slightly attenuated with additional adjustment for BMI and
circulating levels of TNF-a, and IL-6; yet rs7172156, rs1008805,
and rs6493494 remained significantly associated with ranked- and
normal-scale HGF after multiple-comparison corrections
(p#0.04). In the subgroup analysis according to HT use, the 5
observed SNPs were each associated with the ranked- and normal
score-transformed HGF levels in either one of the HT groups, but
none of these SNPs remained significant after correction of
multiple comparisons (corrected p values $0.07).
The 5 variants, which spanned approximately 17 kb, were in
linkage disequilibrium (pairwise D9$97%, r
2$56%). None of
these 5 SNPs remained significant when all of them were included
in the multiple regression model (p value $0.15). The 5 variants
constituted block #6 of the CYP19A1 gene with 2 common
haplotypes accounting for 82% frequency (Figure 2). The first
common haplotype (TCCCA, 42%) containing the minor alleles of
rs7172156 (T) and rs1008805 (C) was significantly associated with
lower HGF levels in either ranked- or normal score-transforma-
tions (corrected p value #0.001), whereas the other haplotype
(CTTTC, 40%) with the minor alleles of rs6493494 (T), rs749292
(T), and rs11636639 (C) was associated with higher ranked or
normal score-transformed HGF levels (corrected p value #0.02,
Table 2). In addition, rs7172156 appeared to be the tagging SNP
for the TCCCA haplotype with its minor allele (T) having similar
frequency and risk estimate to the haplotype. For the CTTTC
haplotype, the rs6493494 was the most plausible SNP whose allele
(T) reflected the frequency and risk estimate for the haplotype.
Discussion
In this exploratory analysis, we evaluated the association
between variants in the CYP19A1 gene, a sex steroid synthesizer,
and plasma levels of a less known adipokine, HGF. The skewness
of HGF distribution was reduced through the transformation into
log, ranked, and normal score scales, which were each regressed
on the gene variants. We found that the ranked and normal-scale
HGF concentrations performed better than the log-scale HGF.
Five of the CYP19A1 gene variants, rs7172156, rs1008805,
rs6493494, rs749292, and rs11636639 were each associated with
ranked- and normal-scale HGF. However, the association of these
5 SNPs with log-scale HGF levels was not significant after
correction for multiple comparisons.
Our findings are the first observational evidence showing an
association between the CYP19A1 gene and HGF levels. One
possible explanation for the association may be due to the
regulation of the aromatase enzyme on HGF secretion. However,
we did not observe an association between the rs700518 SNP
which has been linked to aromatase activity in adipose cells [25]
and HGF levels. Alternatively, estrogen and/or androgen levels
regulated by the aromatase enzyme may mediate the observed
association. In a large study of postmenopausal women, Haiman et
al. reported that the minor alleles of the two tagging SNPs,
rs749292 and rs727479, are associated with a 10%–20% increase
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this study population of women not using hormone therapy, we
did not observe an association between HGF and endogenous
estradiol levels. We also did not find an association between
rs749292 and estradiol levels, although rs6493494 and
rs11636639, two other CYP19A1 variants residing in the same
haplotype block in which rs749292 is located, were weakly
associated with circulating estradiol at pointwise significant level
(uncorrected p values #0.04). The low statistical power (N=147)
may explain the null association among CYP19A1, estradiol, and
HGF levels. Additionally, androgen levels or the ratio of estrogen
over androgen levels may contribute more than estrogen alone to
the association. Of the observed SNPs that were associated with
HGF levels, the rs1008805 SNP has been linked to circulating
testosterone levels in women [23], suggesting a potential role of
androgen in mediating the association. Future studies are
warranted to test the androgen hypothesis.
Previous studies have suggested that the rs749292 variant is
associated with risk for developing female hormone-associated
cancers. A study has reported an elevated risk of ovarian cancer
among Caucasian and Japanese postmenopausal women who
carried both copies of the minor allele (T) of the rs749292 variant
[26]. The other consortium study has also reported an increased
risk for endometrial cancer among Caucasian women carrying the
rs749292 T allele [27]. Both studies have attributed the genetic
association to elevated estradiol concentrations. HGF is an
angiogenic growth factor which promotes cell migration, prolifer-
ation, and invasion [8], and circulating HGF levels tend to be
Figure 1. QQ plots of original (A), log- (B), ranked- (C), and normal score-transformed (D) HGF levels against normal quantiles.
doi:10.1371/journal.pone.0042079.g001
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findings of the potential association between CYP19A1 including
the rs749292 variant and HGF levels suggest that CYP19A1 is also
likely associated with cancer progression due to elevated HGF
levels. Our findings in women who later developed colorectal
cancer also suggest that the observed association between
CYP19A1 and HGF levels may be more relevant to cancer
population. However, our analysis is exploratory and studies with
larger sample size are needed to confirm the association.
Limitations of this study include the small sample size which
likely resulted in the skewness of the HGF distribution and
invalidated the use of statistics such as mean and standard
deviation. Accordingly, we have first conducted the conventionally
used log-scale transformation to reduce the skewed distribution of
HGF. Despite the improvement, the deviation from normality test
for the log- and ranked-transformed HGF distribution remained
significant (p,0.001). We, thus, additionally transformed HGF
concentrations into normal scales to achieve symmetrical and
normally shaped distribution. The small sample size also likely
resulted in the null correlation between HGF (either transformed
or nontransformed) and endogenous estradiol levels among
postmenopausal women in whom estradiol levels tend to be very
low. Given also the null association between the CYP19A1 gene
and endogenous estradiol levels from our study and the other small
study of 345 postmenopausal women [31], a study with larger
sample size such as the one by Haiman and colleagues (.3100
women) [21] may be required for detecting the association.
Alternatively, given that endogenous estradiol is produced through
conversion from androgens in postmenopausal women, it is
possible that androgen levels or the ratio of estrogens over
androgens are also relevant to HGF levels. The lack of androgen
data in this study does not allow for assessment of the mediating
role of androgen in the observed association. Finally, the present
analysis was performed among women who later developed
colorectal cancer. Thus, the findings may not be applicable to the
general population, although both CYP19A1 variants and HGF
levels were not strongly associated with colorectal cancer risk
[32,33].
Conclusion
In summary, our findings of an association between the
CYP19A1 gene variants and circulating HGF levels offer a novel
mechanism underlying the link between obesity and endocrine-
related diseases. Additionally, the CYP19A1 gene may be relevant
to cancer progression, given its potential role in regulating HGF
which has angiogenic and mitogenic properties. However, our
findings are exploratory and require confirmation in larger
observational studies.
Materials and Methods
Study population
The Women’s Health Initiative Observational Study (WHI-OS)
is a large, multifaceted study of 93,676 postmenopausal women
aged 50 to 79 years who were recruited between October 1, 1993
and December 31, 1998 [34]. At baseline, women provided
informed consent and completed questionnaires and a physical
examination. Fasting blood samples were collected, centrifuged,
frozen on site at 270uC, and stored in the specimen repository. In
the present analysis, we included a total of 283 women of
European ancestry with available data on the CYP19A1 gene
variants and HGF levels from two previous studies [32,33]. These
283 women had later developed colorectal cancer after blood
DNA was collected.
HGF biochemical assay
The measurement of plasma HGF levels has been previously
described [35]. Briefly, HGF levels were measured by a multiplex
assay based on Luminex xMAP technology. The interassay
coefficient of variation was 11.7% and the 3-year intraindividual
correlation coefficient was 0.91 [35].
Selection of single nucleotide polymorphism (SNP) and
genotyping
Selection and genotyping of the CYP19A1 variants has been
performed and described previously [32]. Briefly, we first included
42 tagging SNPs that capture common variation and linkage
disequilibrium (LD) structure within the gene region as well as
20 kb upstream and downstream of the gene based on the study
Table 1. Selected characteristics (mean 6 standard deviation or %) among women from the Women’s Health Initiative
Observational Cohort Study (WHI-OS) according to plasma levels of hepatocyte growth factor (HGF).
HGF*
Low (N=86) Medium (N=87) High (N=87) p-value
Median HGF (range), pg/mL 364 (3–499) 629 (500–791) 1119 (796–12857)
Age, year 65.6 (6.9) 64.9 (7.5) 66.7 (6.5) 0.30
BMI, kg/m
2 27.1 (4.7) 27.5 (5.0) 29.7 (6.1) 0.002
Diabetes, % 3.5 5.8 10.3 0.18
Current hormone therapy use, % 54.1 49.4 25.6 ,0.001
IL-6, pg/mL 1.8 (1.5) 1.7 (1.1) 3.0 (2.7) ,0.001
TNF-a, pg/mL 2.5 (1.2) 2.7 (1.6) 7.8 (11.1) 0.001
Estradiol, pg/mL** 11.7 (4.2) 13.2 (8.9) 13.3 (7.7) 0.26
Total IGF1, ng/mL** 142.4 (41.4) 145.7 (56.7) 142.5 (50.4) 0.39
Free IGF1, ng/mL** 0.5 (0.3) 0.5 (0.4) 0.5 (0.4) 0.99
*According to tertile distribution.
**Among non-users of hormone therapy (N=147).
doi:10.1371/journal.pone.0042079.t001
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and additionally through the identification by the Tagger program
[36] using the National Center for Biotechnology Information
Build 35 assembly. Selection of the tagging SNPs was based on a
haplotype frequency (Rh
2)o f$0.70 between observed haplotypes
and those predicted based on tagging SNPs (used in the BPC3
project) or a pairwise correlation coefficient (r
2)o f$0.70 between
tagging SNPs and untyped SNPs (used in the Tagger program),
and a MAF of $1% in the Caucasian populations. We also
included 5 putative functional SNPs obtained through literature
search. All together, there were 47 SNPs selected for this gene.
DNA was extracted from the buffy coat fraction of centrifuged
blood using the QIAmp Blood Kit (Qiagen, Chatsworth, CA) and
genotyping determination was performed with the Sequenom
MassARRAY Genotyping system. Quality control of Sequenom
Genotyping was carried out by repeating the genotyping on 66
duplicate samples with an average concordance rate of 99.7%.
The average genotyping drop-out rates were 6.8%, ranged from
3.1% to 16.9% (Table S1).
In the present analysis, SNPs were excluded from further
analysis if they had a MAF of ,5% or deviated from Hardy-
Weinberg equilibrium (HWE) among all women (p,0.001). We
also excluded individuals who were missing .20% of genotype
data.
Statistical Analysis
Previous studies of HGF levels and health outcomes in the
general population have treated HGF as a categorical variable
[37–39], which avoids problems derived from skewness or extreme
values of the distribution. As the present analysis was based on
continuous HGF levels in which distribution was highly skewed (p
value for normality ,0.001), we transformed HGF concentrations
for all women into a log-, ranked-, or normal score (van der
Waerden (VW) normal score method)-scale value. The practice of
transforming non-normal raw data into a near-normal form is
usually adopted when data are not normally distributed [40]. The
association between the CYP19A1 gene variants and the
transformed HGF concentrations were then assessed through a
linear regression as implemented in PLINK [41] with an additive
scoring for 0, 1, or 2 copies of the minor allele of each SNP. The
analyzed models were adjusted for age (continuous). An empirical
p value was calculated that gave a pointwise estimate of the
significance level of each SNP.
Haplotype LD blocks were constructed using the option of
confidence interval on D9 implemented in Haploview. Haplotype
frequency and expected haplotypes for each subject were then
inferred based on the unphased genotype data using the
expectation-maximization (EM) algorithm in PLINK. We used
linear regression to estimate haplotype-specific association with the
rest of the haplotypes as the referents. Haplotypes with estimated
frequency of ,1% were excluded from the analysis. To control for
comparisons for multiple SNPs (or haplotypes), we performed
10,000 permutations to generate a gene-specific (familywise)
empirical p value for each SNP (or haplotype) and to determine
how frequently the identified association would occur by chance.
We performed these permutations using the max(T) permutation
option in PLINK.
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